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Bone insufficiency remains amajor challenge for bone-anchored implants. The combination of guided bone
regeneration (GBR) and bone augmentation is an established procedure to restore the bone. However, a
proper understanding of the interactions between the bone substitute and GBR membrane materials
and the bone-healing environment is lacking. This study aimed to investigate the early events of bone
healing and the cellular activities in response to a combination of GBR membrane and different calcium
phosphate (CaP) materials. Defects were created in the trabecular region of rat femurs, and filled with
deproteinized bovine bone (DBB), hydroxyapatite (HA) or strontium-doped HA (SrHA) or left empty
(sham). All the defects were covered with an extracellular matrix membrane. Defects were harvested after
12 h, 3 d and 6 d for histology/histomorphometry, immunohistochemistry and gene expression analyses.
Histology revealed new bone, at 6 d, in all the defects. Larger amount of bone was observed in the
SrHA-filled defect. This was in parallel with the reduced expression of osteoclastic genes (CR and CatK)
and the osteoblast–osteoclast coupling gene (RANKL) in the SrHA defects. Immunohistochemistry
indicated fewer osteoclasts in the SrHA defects. The observations of CD68 and periostin-expressing cells
in the membrane per se indicated that the membrane may contribute to the healing process in the defect.
It is concluded that the bone-promoting effects of Sr in vivo are mediated by a reduction in catabolic and
osteoblast–osteoclast coupling processes. The combination of a bioactive membrane and CaP bone
substitute material doped with Sr may produce early synergistic effects during GBR.
Statement of significance
The study provides novel molecular, cellular and structural evidence on the promotion of early bone
regeneration in response to synthetic strontium-containing hydroxyapatite (SrHA) substitute, in combi-
nation with a resorbable, guided bone regeneration (GBR) membrane. The prevailing view, based mainly
upon in vitro data, is that the beneficial effects of Sr are exerted by the stimulation of bone-forming cells
(osteoblasts) and the inhibition of bone-resorbing cells (osteoclasts). In contrast, the present study
demonstrates that the local effect of Sr in vivo is predominantly via the inhibition of osteoclast number
and activity and the reduction of osteoblast–osteoclast coupling. This experimental data will form the
basis for clinical studies, using this material as an interesting bone substitute for guided bone
regeneration.
 2015 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The combination of bone substitute materials and membrane is
commonly used to restore lost or defective bone under the
original treatment concept of guided bone regeneration (GBR).
While the membranes would isolate the bone defect site from
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three-dimensional scaffold to support the osteogenic cells and tis-
sue during bone healing. However, a hypothesis as such remains
speculative, since the mechanisms of bone healing and regenera-
tion, in conjunction with the membrane and bone substitutes, have
not been sufficiently described.
Different types of biomaterials are used as bone substitutes and
as membrane with variable outcomes. Optimizations, for the
predictable outcomes of these biomaterials, require a proper
understanding of the interactions between the substitute and
membrane components with the local host environment. This
includes the influence of the biomaterial properties on the early
cellular and molecular events that determine the onset of tissue
healing and may eventually affect the overall defect restitution.
Deproteinized bovine bone (DBB) is a natural hydroxyapatite
and it is by far the best-documented xenogenic calcium-
phosphate-based material used as a bone substitute. Clinical
studies have reported that DBB promotes bone healing and implant
osseointegration during GBR [1,2]. Nevertheless, other studies have
shown that DBB fails to enhance bone formation or might even
inhibit osseous healing [3,4]. Over the last few years, a substantial
amount of research has been performed to improve the properties
of synthetic calcium phosphate materials. Synthetic hydroxyap-
atite (HA) resembles the chemical composition of the inorganic
component of bone. Nevertheless, the mineral phase of bone is
not purely hydroxyapatite and contains traces of other elements.
The roles of specific elements in bone formation and structure
are not fully understood. It has therefore been suggested that the
incorporation of specific inorganic ions into the scaffold CaP mate-
rial might favorably affect bone regeneration [5]. One example of
importance is strontium (Sr), which has demonstrated favorable
effects on bone quality and strength when administered systemi-
cally. In vitro studies have suggested that Sr has the potential to
increase osteoblastic cell proliferation, gene expression and func-
tional activities [6,7], although the anabolic effect of Sr has been
questioned [8]. Other in vitro studies have suggested that Sr inter-
feres directly with osteoclasts and their resorptive activity [9,10].
Nevertheless, the role of Sr incorporation in HA material on the
in vivo events of early inflammation, bone formation and remodel-
ing needs to be determined.
A rationale to study the interactions between materials and
cells during the early time periods is derived from observations
in vivo which have shown that material properties are rapidly
sensed by material-adherent cells [11]. These interactions
modulate RANKL/OPG/RANK expression, osteoid formation, bone
maturation, osseointegration and implant-bone stability.
The overall objective of this study was to determine the
relationship between early bone regeneration in bone defects
and cellular distribution and activities in association with different
calcium phosphate materials under GBR membrane. The early
molecular and cellular processes, potentially involved in GBR, were
investigated in a rat femur model using a novel strontium-doped
hydroxyapatite (SrHA) compared with hydroxyapatite (HA) and
deproteinized bovine bone (DBB). The cellular and molecular activ-
ities were related to the overall early bone formation and to the
spatial distribution of the newly formed bone. The aims were,
firstly, to determine whether the presence of bone substitutes in
membrane-covered defects alters the early bone formation, com-
pared with empty, membrane-covered defects. Secondly, does
the presence of Sr ions in the HA affect the early cellular and
molecular activities in the defect and, if so, does this relate to the
amount and distribution of the new bone? In addition, a third
aim was to explore whether monocytes/macrophages and osteo-
progenitors are distributed in the membrane per se.2. Material and methods
2.1. Materials
Deproteinized bovine bone (DBB; Bio-Oss) was purchased from
Geistlich Pharma AG (Wolhusen, Switzerland). For the in-house
preparation of the hydroxyapatite (HA) and the strontium-doped
hydroxyapatite (SrHA), calcium chloride, strontium nitrate,
diammonium hydrogen phosphate and ammonia solution were
purchased from Sigma–Aldrich (USA). All the chemicals were ana-
lytical grade reagents used as received without further purification.
2.1.1. Preparation of powders (HA, SrHA005, SrHA025 and SrHA050)
Firstly, HA powder was synthesized using a standardized pre-
cipitation method. In short, 0.2 M of diammonium hydrogen phos-
phate solution (S1) and 0.33 M of calcium nitrate solution (S2)
were prepared separately. The Ca/P ratio and the pH value were
adjusted to 1.67 and 10 respectively. The S1 was gradually added
to S2 by stirring. The precipitation was kept for 24 h before filtra-
tion and washing. Finally, the precipitation was washed twice with
distilled water and once with ethanol, before drying at 60 C in a
vacuum oven. The SrHA powder was prepared in the same way
but also with the addition of strontium nitrate to the S2 solution.
For characterization purposes, SrHA powders with three levels of
Ca substitution by Sr were prepared: 5% (SrHA005), 25% (SrHA025)
and 50% (SrHA050). This was achieved by controlling the ratios of
the Ca and Sr in the solution.
2.1.2. Preparation of granules (HA, SrHA005, SrHA025 and SrHA050)
The prepared HA, SrHA005, SrHA025 and SrHA050 powders
were made into paste by mixing them with 0.6 wt% cellulose solu-
tion. The obtained pastes were injected into pores of Teflon plate
with a thickness of 1.5 mm. The injected pastes were dried at
37 C for 1 d. The as-prepared column-shaped granules (1.5 mm
diameter) were then carefully removed from the Teflon plate and
heat-treated (calcinated) at 1000 C for 1 h. The obtained granules
were then pulverized and sieved, using meshes, in order to obtain
smaller granules with a size comparable to that of the DBB (in the
range of 400–600 lm).
2.1.3. Characterizations of the granules (DBB, HA, SrHA005, SrHA025
and SrHA050)
All granule types were characterized with respect to surface
area, crystallinity, in vitro degradation and in vitro ion release.
Details about the different procedures and results of the character-
izations are provided in the Supplementary material (Appendix A)
and Supplementary Fig. S1. The results of the characterization tests
showed that SrHA050 granules had a high release of Sr but not Ca
or P, while displaying a surface area and degradation rate compa-
rable to that of the HA granules. SrHA050 was therefore selected
from the three groups with different Sr concentrations and desig-
nated as SrHA in the further characterizations (surface morphology
and chemical composition) and in the in vivo studies.
2.1.4. Surface morphology and chemical composition of granules (DBB,
HA, SrHA)
The morphology of the granules was analyzed using a field-
emission scanning electron microscope (FESEM, LEO 1550) work-
ing at 5 kV. The chemical composition of the different granules
and the number of different ions in each granule type were ana-
lyzed by inductively coupled plasma atomic emission spectroscopy
(ICP-AES). In short, the granules were dissolved in 1 M of HCl
solution and analyzed by ICP-AES.
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2.2.1. Pre-testing in polyurethane foam
The amount of each granule type (DBB, HA and SrHA) needed to
fill a comparable defect size in the animal model was estimated by
filling holes created in solid rigid polyurethane foams (Sawbones,
Pacific Research Laboratories, Vashon, USA). The holes were created
in the polyurethane foam block using a trephine (2.3 mm diameter
and 3 mm penetration depth). An optimum amount of each granule
type was then incrementally added to the holes, ensuring complete
filling. Thereafter, the weight of each granule type needed to fill the
standardized defect size was measured. The mean weight of DBB,
HA and SrHA was 1.1, 2.3 and 1.4 mg, respectively.2.2.2. Animal surgery
The animal experiment was approved by the University of
Gothenburg Local Ethics Committee for Laboratory Animals (dnr
279/2011). A total of 84 male Sprague–Dawley rats (Charles River,
Sulzfeld, Germany) were used. The average weight ranged between
320 and 350 g. The handling of animals and the surgical protocol
has previously been described in detail [11]. In brief, the surgical
procedure was performed under inhalation general anesthesia
and a local injection of xylocaine. A defect was made in each
femoral epiphysis (trabecular bone region) using a trephine with
a 2.3 mm internal diameter and 3 mm penetration depth under
generous irrigation with NaCl 0.9%. Bone harvested from the defect
site was collected from the trephine and preserved in RNA preser-
vation medium for the determination of baseline gene expression
(BL; n = 8). Each defect was filled with deproteinized bovine bone
(DBB), hydroxyapatite (HA) or strontium-doped hydroxyapatite
(SrHA) granules or left empty (sham). All defects, filled and empty,
were then covered using an extracellular membrane derived from
porcine small intestinal submucosa (DynaMatrix, Keystone
Dental, Burlington, MA, USA) (Fig. 1). The four experimental groups
were randomized, ensuring equal distribution and rotation among
the animals and between right and left locations. The retrieval pro-
cedure was performed at 12 h, 3 d and 6 d (28 rats at each time
point). The skin was re-opened and the experimental sites were
identified. Sites intended for gene expression analysis were
retrieved using a 2.3 mm trephine. The samples were immediately
preserved in tubes containing RNAlater (n = 8 per group at each
time point). Sites designated for histology and immunohistochem-
istry were harvested en bloc using a dental disc. The harvested
samples were then immersed in formalin (n = 6 per group at each
time point).2.2.3. Histology and immunohistochemistry
After fixation, the blocks were decalcified in 10% EDTA for 10 d.
Thereafter, the decalcified blocks were dehydrated twice in 70%Fig. 1. The surgical procedure. The micrographs show the stepwise surgery: (A) site e
membrane applied.ethanol and four times in iso-propylalcohol, for 1 h each.
Subsequently, paraffin was infiltrated into the samples using liquid
paraffin at 56–58 C, 3 times for 1 h. After paraffin embedding, sec-
tions with a thickness of 3–5 lm were produced using a micro-
tome, then mounted on glass slides and stained with
hematoxylin and eosin for light microscopy.
For immunostaining, 3–5 lm paraffin-embedded sections were
mounted on polylysine slides (Menzel GmbH and Co KG,
Braunschweig, Germany). The sections were deparaffinized,
hydrated and incubated with primary antibodies CD68
(sc-58965, Santa Cruz Biotechnology, USA) and periostin
(ab14041, Abcam, UK). The CD68 targeted mononuclear cells
(monocytes/macrophages), as well as multinucleated giant cells
and osteoclasts. The periostin was used as a marker of
osteoprogenitor cells and intramembranous bone formation [12].
Negative control slides were prepared by the omission of the pri-
mary antibody and incubation with 1% BSA in PBS. The immunore-
activity of CD68 and periostin was detected and visualized using
Betazoid DAB Chromogen kit and horseradish peroxidase (HRP)
(Biocare Medical, USA). The relative proportions of the CD68 posi-
tive cells were semi-quantitatively scored as three major subcate-
gories: (i) mononuclear, monocyte/macrophage phenotypes, (ii)
multinuclear, osteoclast phenotypes (associated with bone remod-
eling site) and (iii) multinuclear giant cell phenotypes (associated
with material or in soft tissue). The counting procedure was
applied (objective 20). The number of cells/mm2 was determined
and the total amount was then calculated with respect to the total
defect area. The periostin staining was evaluated qualitatively.2.2.4. Histomorphometry
For histomorphometry, the paraffin-embedded blocks were re-
embedded in acrylic resin (LR White) (London Resin Company Ltd,
Berkshire, UK). The long axis of the defect was cut using a diamond
saw. Ground sections were prepared using sawing and grinding
(Exakt Apparatebau GmbH & Co, Norderstedt, Germany). Sections
with a final thickness of 10–20 lm were stained with 1% toluidine
blue. All sections were coded and evaluated blindly for histology
and histomorphometry. Histomorphometry was performed using
a 10 objective in a light microscope (Nikon Eclipse E600 Nikon
Ltd., Tokyo, Japan) and image software (ACT-1; Nikon Ltd., Tokyo,
Japan) and analytical software (Easy Image Measurement 2000;
Bergman Labora AB, Huddinge, Sweden). The amount of newly
formed bone in the defect was determined using a counting proce-
dure. A software grid consisting of 16 zones (800 lm  800 lm
each) was superimposed over the tissue and the percentage area
occupied by newly formed bone was calculated. In order to esti-
mate the relative proportion and distribution of the bone in the
defect, the following regions were identified: (I) the entire defect,
represented by the 16 zones of the grid; (II) a peripheral regionxposed; (B) defect prepared; (C) example of bone substitute (HA) introduced; (D)
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the defect) and a central region (C, represented by zones covering
the center of the defect); (III) a top region (top, represented by the
upper zones adjacent to the membrane), followed by a middle level
(middle) and bottom level (bottom). The bone area was deter-
mined separately in every zone and the area percentage was then
calculated with respect to the total defect area or to the respective
region (central, peripheral, top, middle, bottom).
2.2.5. Quantitative polymerase chain reaction (qPCR)
Total RNA from the trephine-retrieved samples was extracted
using an RNeasyMini kit (QIAGENGmbH, Hilden, Germany) accord-
ing to previously published detailed procedure [11]. Reverse tran-
scription was carried out using a GrandScript cDNA Synthesis kit
(TATAA Biocenter AB, Gothenburg, Sweden) and universal RNA
Spike (TATAA, Biocenter AB). The RNA concentration of each sample
was normalized to 20 ng/ml before the reverse transcription. The
design of primers for nine target genes, tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6), monocyte chemoattractant protein-1
(MCP-1), chemokine receptor type 4 (CXCR-4), alkaline phosphatase
(ALP), osteocalcin (OC), receptor activator of NF-kappaB ligand
(RANKL), calcitonin receptor (CR) and cathepsin K (CatK), as well
as for five putative reference genes, was performed using Primer3
software. Referencegene screeningwasperformedon tenbone sam-
ples (two of each type) from each time point. The RNA quality of
these samples was analyzed with a Nano 6000 RNA kit by Bioanaly-
ser 2100 Electrophoresis System (Agilent Technologies). The expres-
sion profiles of the putative reference genes were evaluated using
geNorm and Normfinder software (GenEx ver.6, Multid Analyses
AB, Gothenburg, Sweden), in order to determine the best referenceFig. 2. Morphological evaluation of the substitute materials. The photographs (A–C) and
granules used to augment the bone defects. (A, D and G) show the deproteinized bovi
strontium-doped hydroxyapatite (SrHA).gene for normalization. The primer design parameters were in
accordance with previously described procedure [11]. Real-time
PCR was performed in duplicate using the CFX 96 Real time System
(BIO RAD laboratories) with Grandmaster SYBRmix (TATAA Biocen-
ter, Sweden) in 10 ll reactions. The cycling conditionswere 95 C for
30 s, followedby 40 cycles of 95 C for 5 s, 60 C for 15 s and 72 C for
10 s. The fluorescence was read at the end of the 72 C step. Melting
curves were recorded after the run by a stepwise temperature
increase (1 C/5 s) from65 to95 C.All plateswere runwith an Inter-
plate calibrator (TATAA Biocenter, Sweden) to compensate for vari-
ations between runs. Both geNorm and Normfinder identified the
gene hypoxanthine phosphoribosyltransferase 1 (HPRT1) as the
most stable in the present experimental study. Quantities of the tar-
get geneswere normalized to HPRT1. The normalized relative quan-
tities were calculated using the delta-delta Cq method and 90% PCR
efficiency (k * 1.9DDCq).
2.3. Statistical analysis
For histomorphometry and gene expression analyses, statistical
comparisons were made between the four groups and between the
different time points for each group. Moreover, the gene expres-
sion in the four groups was compared with the constitutive (base-
line; BL) gene expression. A non-parametric Kruskal–Wallis test
was used to identify statistical differences between the experimen-
tal groups or the time points. Whenever a statistical difference was
found, the Mann–Whitney test was applied. Analyses were made
using SPSS Version 10 software (SPSS, Inc., Chicago, USA) and the
significance was set at p < 0.05. The data are presented as the
mean ± standard error of the mean.scanning electron microscopy images (D–I) show the morphology of the different
ne bone (DBB); (B, E and H) show the hydroxyapatite (HA); (C, F and I) show the
Table 1
Chemical compositions of deproteinized bovine bone (DBB), hydroxyapatite (HA) and
strontium-doped hydroxyapatite (SrHA) granules analyzed by inductively coupled
plasma atomic emission spectroscopy (ICP-AES).
Material Ca (mg/g) Mg (mg/g) P (mg/g) Si (mg/g) Sr (mg/g)
DBB 371 6.5 176 3 0.3
HA 364 0.2 190 0.09 44
SrHA 275 0.2 178 0.09 207
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3.1. Surface morphology and composition of the different granules
Macroscopically, the DBB, HA and SrHA had a relatively similar
appearance in terms of size range and surface irregularity
(Fig. 2A–C). The SEM analysis at lower magnification showed that
the individual DBB granules (Fig. 2D) had a greater variation in
shape but presented a smoother surface than the HA and SrHA
(Fig. 2E and F). No major difference between the HA and SrHA
was observed at this magnification level. At higher magnification,
whereas DBB (Fig. 2G) and SrHA (Fig. 2I) revealed a homogenously
granular surface appearance, the HA (Fig. 2H) showed a combina-
tion of large and small grains. At this magnification, the DBB
showed a smoother texture/curvature of the surface, whereas both
the HA and SrHA displayed relatively sharp, needle-like structures.
The data describing the elemental compositions of each granule
type (DBB, HA and SrHA) are shown in Table 1.3.2. Histology and immunohistochemistry
At 12 h, the sham defect was mainly occupied by hematoma,
whereas the augmented defects were occupied by evenly dis-
tributed bone substitutes (DBB, HA or SrHA). All substitutes were
surrounded by hematoma consisting mainly of erythrocytes and
a few strands of fibrin. Immunostaining at this time point revealed
mononuclear, CD68-positive, monocytes/macrophages (Fig. 4), as
well as periostin-positive osteoprogenitors, exhibiting a rounded
shape (Fig. 5). No major differences in the relative proportion of
the monocytes/macrophages (Table 2) or the osteoprogenitors
were observed between the different experimental groups (sham,
DBB, HA and SrHA).
At 3 d, the sham defect was occupied by a more organized
hematoma, characterized by erythrocytes trapped in a dense fibri-
nous network (Fig. 3). In all bone substitute groups, the granules
occupied a large portion of the defect and were confined within
the boundaries of the defect (Fig. 3). The immunostaining showedFig. 3. Histology of the defects treated with membrane alone or membrane in combinat
four bone defect groups at 3 days (A–D) and 6 days (E–H) of implantation. The defects w
(DBB; B and F), hydroxyapatite granules (HA; C and G) or strontium-doped hydroxyapatit
ob = old bone; nb = new bone.that the relative proportion of CD68-positive monocytes/
macrophages had increased considerably in all groups (Fig. 4).
Scoring of these cells revealed that the higher increase was general
in all substitute groups and to a lesser extent in the sham (Table 2).
At this time point, periostin immunostained cells assumed more
elongated, spindle-shaped morphology (Fig. 5). Moreover, diffuse
staining of periostin was evident, predominantly at the surfaces
of bone trabeculae bordering the defects. Diffuse staining of perios-
tin was also detected interstitially in the intergranular tissues
(Fig. 5). This diffuse staining of periostin, at 3 d, strongly indicated
the earliest signs of intramembranous bone formation, which was
not detected in the hematoxylin- and eosin-stained or toluidine
blue-stained sections.
The HA group, at 6 d, was excluded from all immunohistochem-
ical analyses due to poor quality sections for the cellular evalua-
tions or counts. For the other groups (sham, DBB and SrHA) at
6 d, the hematoma observed in earlier time periods had been
replaced by a well-organized granulation tissue rich in spindle-
shaped cells (Figs. 3 and 5). In spite of this, the hematoma could
still be observed in the central region of the sham defect (Fig. 3).
The diffuse staining of periostin indicated a further increase in
the amount and intensity, at the expense of the individually
stained cells (Fig. 5). In parallel with the increased diffuse staining
of periostin, new (woven) bone formation was observed in the
sham defect and also in conjunction with all materials (DBB and
SrHA) as judged using regular histology at 6 d (Fig. 6). The new,
woven bone was preferentially localized at the periphery rather
than in the center of the defects (Fig. 6). The SrHA group displayedion with the different bone substitute materials. The survey micrographs show the
ere either empty (sham; A and E) or filled with deproteinized bovine bone granules
e granules (SrHA; D and H). St = soft tissue; m = membrane; gr = granule; d = defect;
Fig. 4. Immunohistochemical analysis of CD68 reactivity in the defects treated with membrane alone or membrane in combination with the different bone substitute
materials. The survey micrographs show selected central and peripheral regions of the defects treated with the membrane alone (sham; A–C) or the membrane in
combination with deproteinized bovine bone granules (DBB; D–F), hydroxyapatite granules (HA; G and H) or strontium-doped hydroxyapatite granules (SrHA; I-K). The
analysis was performed at 12 h (A, D, G and I), 3 days (B, E, H and J) and 6 days (C, F and K) of implantation. The membrane with hydroxyapatite granules (HA) group at 6 days
was excluded from this analysis due to technical limitations in obtaining proper paraffin-embedded sections. Black arrowheads = bone-related multinucleated cells
(osteoclasts); Black arrows = material-related multinucleated cells; ob = old bone; nb = new bone; d = defect; gr = granule.
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regions in the other defects. Moreover, in the sham defects, the
woven bone was restricted to the original bone at the periphery
of the defect and was seldom detected centrally. In contrast, for
all bone substitutes, islets of woven bone were also detected in
the central region of the defect, lining the circumference of the
granules. The border between the new bone and the DBB granules
was clearly distinguishable. In contrast, in the case of the SrHA, the
boundary was less easily distinguished and the woven bone occa-
sionally appeared to reach into the surface irregularities of the
granules.
With respect to CD68 immunostaining at 6 d (Fig. 4), it was
noteworthy that an increase in the CD68-stained mononuclear
monocytes/macrophages was observed in the sham defects. Thisresulted in the almost doubling of these cells in the sham com-
pared with 3 d (Table 2). An important, exclusive observation at
the 6 d time point was the appearance of many CD68-positive
multinucleated cells within the boundaries of the different defects
(Fig. 4). These multinucleated cells were seen repeatedly in two
different relationships. The first was their close association with
apparently active bone remodeling sites, characterized by resorp-
tion lacunae in the bone underneath these cells and osteoblastic
seams depositing new bone (Fig. 4). The second was the appear-
ance in association with substitute materials (SrHA and DBB) or
scattered in the intergranular tissue between the granules of these
materials (Fig. 4). The former were considered to be active osteo-
clasts, whereas the latter were referred to as multinucleated giant
cells (MNGCs). The material-related MNGCs were more commonly
Fig. 5. Immunohistochemical analysis of periostin reactivity in the defects treated with membrane alone or membrane in combination with the different bone substitute
materials. The survey micrographs show selected regions of the defects treated with the membrane alone (sham; A–C) or the membrane in combination with deproteinized
bovine bone granules (DBB; D–F), hydroxyapatite granules (HA; G and H) or strontium-doped hydroxyapatite granules (SrHA; I–K). The analysis was performed at 12 h (A, D,
G and I), 3 days (B, E, H and J) and 6 days (C, F and K) of implantation. The membrane with hydroxyapatite granules (HA) group at 6 days was excluded from this analysis due
to technical limitations in obtaining proper paraffin-embedded sections. Black arrows = staining of osteoprogenitors; black arrowheads = diffuse staining of the
intramembranous bone formation; ob = old bone; nb = new bone; d = defect; gr = granule.
Table 2
Immunohistochemical analysis of CD68-positive monocytes/macrophages in the
defects treated by membrane alone (sham) or the membrane in combination with
deproteinized bovine bone (DBB), hydroxyapatite (HA) or strontium-doped hydrox-
yapatite (SrHA) granules after 12 h, 3 days and 6 days of healing.
Sham DBB HA SrHA
12 h + + + +
3 days ++ +++ +++ +++
6 days +++++ ++++ ND ++++
Labeling: + = 1–100 cells/mm2; ++ = 101–200 cells/mm2; +++ = 201–400 cells/mm2;
++++ = 401–800 cells/mm2; +++++ > 800 cells/mm2; ND = not done.
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(Table 3). On the other hand, the CD68-positive osteoclasts were
equally present in the sham and DBB groups, but there wereconsiderably fewer in the SrHA group (Table 3). The MNGCs were
seldom found in the sham defects.3.3. Histomorphometry
The relative proportion of the newly formed (woven) bone was
determined in the total defect area (Fig. 6), as well as in different
regions of the defect (Fig. 6). Despite the generally low percentage
of newly formed woven bone (ranging between 4% and 7.3% of the
total defect area), the histomorphometric analysis revealed a sig-
nificantly higher total bone area percentage in SrHA-treated
defects (7.3 ± 0.6) compared with sham (3.7 ± 0.8).
The topological measurements at 6 d showed a higher propor-
tion of new bone at the periphery (calculated per the peripheral
Fig. 6. Histology and histomorphometry of the defects treated with membrane alone or the membrane in combination with the different bone substitute materials. The light
micrographs show the pattern of new bone (nb) formation in the top (A–D), middle (E–H) and bottom (I–L) regions of each defect (d) at 6 days of implantation. The defects
were either empty (sham) (A, E and I) or filled with deproteinized bovine bone granules (DBB) (B, F and J), hydroxyapatite granules (HA) (C, G and K) or strontium-doped
hydroxyapatite granules (SrHA) (D, H and L). Resorbable ECM membrane (m) was placed over each defect, above the granules (gr). The column graphs show the
histomorphometric measurement of the new bone area in the entire defect (M), peripheral and central regions (N), as well as in the top, middle and bottom regions (O) of the
defect. Statistically significant difference (p < 0.05) indicated by asterisk (⁄). The schematic diagrams show the defect and the area of measurements for histomorphometry. A
software rectangular grid consisting of sixteen zones covered the entire area of the defect. C = central region; P = peripheral region. ob = old bone.
416 I. Elgali et al. / Acta Biomaterialia 29 (2016) 409–423area) compared with the bone proportion found centrally in the
respective central area. The SrHA demonstrated a significantlyhigher proportion of new bone in the peripheral region
(9.5 ± 1.2%), compared with that found in the peripheral region of
Table 3
Immunohistochemical analysis of CD68-positive multinucleated cells in the defects
treated by membrane alone (sham) or the membrane in combination with depro-
teinized bovine bone (DBB), hydroxyapatite (HA) or strontium-doped hydroxyapatite
(SrHA) granules after 6 days of healing.
Sham DBB HA SrHA
Bone-related multinucleated cells (osteoclasts) ++ ++ ND +
Material-related multinucleated cells  ++ ND +++
Labeling:  = no cells; + = 1–5 cells/mm2; ++ = 6–10 cells/mm2; +++P 10 cells/
mm2; ND = not done.
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also seen at the top level, in close proximity to the lower surface of
the membrane, but no significant differences were detected
between the groups.3.4. Histology and immunohistochemistry of the membrane
compartment
At all time points, the membrane was localized above the defect
separating the top granules or bone tissue from the overlying soft
tissue (Fig. 3). At all time points (12 h, 3 d and 6 d; Figs. 7 and 8),
mononuclear cells were evident inside the membrane, assumingFig. 7. Immunohistochemical analysis of CD68 reactivity in the membrane compartment
membrane in combination with deproteinized bovine bone (DBB; D–F), hydroxyapatite (
hydroxyapatite granules (HA) group at 6 days was excluded from this analysis due to tec
show the CD68-positive cells in the membrane compartment at 12 h (A, D, G and I), 3 daccess and migration through the peripheral borders, between
the separated collagen layers of the membrane, rather than directly
across the membrane. Immunostaining with CD68 (Fig. 7) and
periostin (Fig. 8) revealed the existence of monocytes/
macrophages and osteoprogenitors inside the membrane through-
out the healing period. Both CD68 and periostin reactivity
appeared to be restricted to well-defined mononuclear cells where
neither multinuclear staining with CD68 nor diffuse staining with
periostin was observed inside the membrane.
3.5. Gene expression in the different defects
Comparisons were made of gene expression in bone retrieved
during the defect preparation (baseline; BL) and the tissue har-
vested from the sham and filled defects after 12 h, 3 d and 6 d.
Selected examples of genes involved in the early events of bone
healing, including cell recruitment and inflammation, bone forma-
tion and remodeling (Fig. 9), were analyzed.
3.5.1. Gene expression of cell recruitment and inflammation markers
(Fig. 9)
3.5.1.1. Baseline and temporal changes in gene expression. Generally,
the cell recruitment chemokines, MCP-1 and CXCR4, and theabove the defect. The defects were treated with membrane alone (sham; A–C) or the
HA; G and H) or strontium-doped hydroxyapatite (SrHA; I–K). The membrane with
hnical limitations in obtaining proper paraffin-embedded sections. The micrographs
ays (B, E, H and J) and 6 days (C, F and K) of defect healing.
Fig. 8. Immunohistochemical analysis of periostin reactivity in the membrane compartment above the defect. The defects were treated with membrane alone (sham; A–C) or
the membrane in combination with deproteinized bovine bone (DBB; D–F), hydroxyapatite (HA; G and H) or strontium-doped hydroxyapatite (SrHA; I–K). The membrane
with hydroxyapatite granules (HA) group at 6 days was excluded from this analysis due to technical limitations in obtaining proper paraffin-embedded sections. The
micrographs show the periostin-positive cells in the membrane compartment at 12 h (A, D, G and I), 3 days (B, E, H and J) and 6 days (C, F and K) of defect healing.
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expression levels at all evaluated time points compared with the
constitutive BL level, irrespective of the experimental groups
(sham, DBB, HA or SrHA), and they were significantly reduced
thereafter. In fact, the expression of IL-6 and MCP-1 in the BL
was comparatively negligible. The peak expression of TNF-a, IL-6
and CXCR4 observed at 12 h revealed a significant reduction after
3 d, for all groups, but it was still significantly higher compared
with the BL levels of these genes. A similar temporal trend was
observed for MCP-1, but the temporal change from 12 h to 3 d
was not statistically significant. From 3 d to 6 d, whereas CXCR4
and IL-6 maintained similar levels for all groups, TNF-a showed a
further significant reduction to the lowest levels for all experimen-
tal groups. The MCP-1 was also significantly reduced from 3 d to
6 d for all groups except for the DBB group where no statistically
significant change was observed.
3.5.1.2. Comparative gene expression between the groups. At 12 h,
the SrHA significantly reduced the expression of IL-6, six-fold and
two-fold, compared with the sham and HA, respectively. At the
same time, DBB resulted in a two-fold significant upregulation of
TNF-a when compared with the sham and HA. At 3 d, a 1.5-foldsignificantly lower expression of TNF-a was demonstrated in the
SrHA and DBB groups when compared with the HA group.
Moreover, the expression of CXCR4 was 1.6-fold significantly lower
in the SrHA compared with the sham. At 6 d, no significant differ-
ences were detected for any of the pro-inflammatory genes or cell
recruitment genes between the different groups.
3.5.2. Gene expression of bone formation and bone resorption markers
(Fig. 9)
3.5.2.1. Baseline and temporal changes in gene expression. In contrast
to the expression profile of the pro-inflammatory cytokines, the
expression of all selected bone-formation and remodeling genes
was characterized by high constitutive expression at BL that was
significantly downregulated after 12 h for all groups (sham, DBB,
HA and SrHA). After 3 d, whereas the expression levels of bone-
formation genes (ALP and OC) remained significantly lower than
the constitutive BL, the expression of remodeling genes (CR and
RANKL) in all groups recovered to levels similar to the BL, except
for the SrHA, where they remained significantly lower than the
BL. After 6 d, the expression of bone-formation genes demon-
strated an equal increase in all groups, reaching significantly
higher levels than the BL. In parallel, the expression of the
Fig. 9. Gene expression analysis of pro-inflammatory and cell recruitment, bone formation, bone resorption and remodeling markers in the bone defects after 12 h, 3 days and
6 days of healing. The defects were treated with membrane alone (sham) or the membrane in combination with deproteinized bovine bone (DBB), hydroxyapatite (HA) or
strontium-doped hydroxyapatite (SrHA). Statistically significant differences (p < 0.05) are indicated by the small letters: a = significant difference from baseline (BL);
b = significant difference from sham; c = significant difference from DBB; d = significant difference from HA. TNF-a = tumor necrosis factor; IL-6 = Interleukin 6; MCP-
1 = monocyte chemoattractant protein-1; CXCR4 = chemokine receptor type 4; ALP = alkaline phosphatase; OC = osteocalcin; CR = calcitonin receptor; CatK = cathepsin K;
RANKL = receptor activator of nuclear factor kappa-B ligand.
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cantly exceed the BL level, with no major variation among the
experimental groups. However, after 6 d, although the expression
of CatK in all groups was maintained at a level similar to the BL,
the osteoclastic surface marker, CR, was significantly lower than
the BL. From 12 h to 3 d, a significant temporal increase was
demonstrated for all osteoclastic genes (CR and CatK) in all groups.
In parallel, from 12 h to 3 d, no major temporal change was
observed in the expression of bone formation genes (ALP and OC)
in any of the groups. From 3 d to 6 d, this relationship was
reversed, whereby the expression of bone-formation genes (ALP
and OC) significantly increased and the expression of osteoclastic
genes (CR and CatK) did not change significantly for any group.
The RANKL expression revealed a constant significant increase for
all groups from 12 h to 3 d and from 3 d to 6 d.3.5.2.2. Comparative gene expression between the groups. With
regard to the expression of bone-formation markers (ALP and
OC), no major significant differences were found between the dif-
ferent groups at any time point. At 12 h, the expression of RANKL
was not detected in the defects with bone substitutes (DBB, HAand SrHA), while a significantly high level was demonstrated in
the sham, unfilled defect. At this time point (12 h), the CR expres-
sion was also not detected in all groups, irrespective of whether
they were filled or unfilled. No major differences were observed
in the detected CatK expression levels between the groups at
12 h. At 3 d, the expression levels of CR and RANKL were 1.7- to
two-fold and 2.5- to four-fold significantly lower in the SrHA com-
pared with the other groups. The CatK expression was about 1.8- to
two-fold lower in the SrHA and sham groups compared with the
DBB and HA. At 6 d, the SrHA further demonstrated a 1.7- to
five-fold lower expression of CR when compared with the other
groups.4. Discussion
The present study investigated the early molecular and struc-
tural events of bone healing in trabecular bone defects treated with
naturally derived resorbable membrane with and without different
bone substitutes. One major histological finding was the increased
level of total bone formation, at 6 d, with SrHA granules.
Interestingly, no significant added benefit of DBB and HA
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ison to the membrane-covered, empty defect. Since all the defects
were covered with a membrane, one possible explanation is that
the membrane had created an optimal environment that promoted
intra-membranous bone formation, even in the absence of intro-
duced scaffolding materials. In support, a similar defect treated
with only HA or SrCaP substitutes failed to generate new bone at
early (6 d) but not late (28 d) time points, in the absence of a mem-
brane [13]. Although both DBB and HA promote bone formation
and defect restitution over time [14–16], the present results indi-
cate that these materials are not optimal, osteoinductive materials,
able to rapidly trigger osteogenesis and the filling of bone defects.
The mechanism for the enhanced bone formation induced by
the presence of SrHA granules in the defect was explored. As
judged by the results of the early (before 7 d) Ca, P and Sr ion-
release patterns in vitro, the release of Sr was the main difference
between SrHA and HA granules. One major explanation for the
increase in the early amount of bone in association with the SrHA
was the inhibition of osteoclastic differentiation and activity, as
judged by the significant reduction in CR, the osteoclast receptor
marker, and CatK, the osteoclast activity marker at 3 d and 6 d,
compared with the HA. On the other hand, SrHA did not influence
the anabolic activity (ALP and OC) in the defect differently from the
other substitutes. This is in partial agreement with recent observa-
tions in vitro, [8]. The latter study confirmed a marked reduction in
osteoclast number whereas no major change in the ALP activity or
osteoblast number was observed when the cells were exposed to Sr
ranelate in range of 0.1–1 mM, which is comparable to the Sr levels
released by the present SrHA (0.2–1.5 mM; 3–7 d, respectively)
in vitro. However, a major difference between the results of the
two studies was the significant reduction of mineralization in the
osteoblast culture [8]. Nevertheless, by virtue of the significant
reduction in RANKL expression observed in the present study, it
is possible that the major effect of Sr on osteoblasts was exerted
through the de-coupling of the osteoblast–osteoclast cross-talk.
This finding adds to previous observations that the presence of
SrCaP materials significantly reduces the osteoclast gene expres-
sion but not the anabolic, osteoblast gene expression [13]. In the
latter study, Sr did not affect RANKL expression at 6 d and 28 d,
which indicates that the Sr effect on RANKL expression takes place
during the very early time period (3 d).
Further supporting evidence of an interaction between Sr and
osteoclasts was the observed reduction in the number of CD68
immunoreactive, multinuclear giant cells localized at resorption
sites. Interestingly, SrHA was associated with an increase in the
number of cells with a similar immune phenotype localized at
the surface of the SrHA substitute. The interpretation of these find-
ings is that the presence of Sr does not interfere with the formation
of multinucleated giant cells. Multinucleated cells are either osteo-
clasts, which are differentiated from monocytes via specific intra-
cellular signaling pathways [17], or ‘‘foreign-body giant cells”,
which are formed as a result of the fusion of multiple macrophages
after frustrated phagocytosis [18,19]. In the present study, these
cells were defined in the defect by immunostaining using CD68
antibody, which is a marker of all cell phenotypes of monocyte lin-
eage, including macrophages, foreign-body giant cells and osteo-
clasts [19,20]. In fact, the multinucleated cells in the defects
were detected in association with either the bone or the surface
of the implanted granules. The bone-related multinuclear cells
were assumed to be osteoclasts, based on their histological charac-
teristics, proximity to newly formed bone and formation of resorp-
tion lacunae, although the osteoclastic phenotype of these cells
was not further investigated in this study. At present, it is not pos-
sible to determine whether the multinucleated, CD68-positive cells
localized on the surface of the substitute materials are osteoclasts.
Previous studies of the phenotype of multinucleated giant cellsaround HA particles after implantation in rat bone defects have
shown that these cells exhibit neither the morphologic nor the
enzymatic and functional characteristics of the osteoclast [21].
Clinical, oral bone specimens have shown that synthetic HA is
associated with more multinucleated giant cells compared with
DBB [22]. There is evidence that ‘‘foreign-body giant cells” also pro-
duce vascular endothelial growth factor, which is an important
molecule for angiogenesis during bone healing [22,23]. The signif-
icance of these material-related giant cells in relation to material
degradation, repair and bone regeneration awaits clarification. In
spite of this, their formation appears to be an integral process in
the early period of bone regeneration with calcium phosphate sub-
stitutes. Taken together, the present and previous results show
that synthetic SrHA is associated with lower osteoclast numbers
and reduced osteoclast activity but a relatively large number of
material-associated multinuclear giant cells.
The current results support pre-clinical and clinical data show-
ing no difference in the osteogenic potential between the natural
HA (DBB) and the synthetic HA [14–16]. Furthermore, the different
materials revealed distinct patterns of bone distribution. In rela-
tion to the membrane-covered empty defect, a significantly larger
and substantial amount of new bone formation had taken place in
the peripheral and bottom parts of the defect in conjunction with
the SrHA. Comparable data were reported in another recent study,
where bone regeneration in association with HA was compared
with strontium-doped calcium phosphate in a rat bone defect
[13]. In the latter study, performed during a late time period
(28 d), SrCaP induced a larger amount of bone in the periphery of
the defects, whereas the HA promoted high bone regeneration cen-
trally. One possible explanation for these different bone distribu-
tion patterns could be the release of strontium that was assumed
to diffuse in the defect in a concentration gradient, with a low opti-
mal level at the periphery and a high, perhaps even detrimental
level at the center. In vitro studies show that the Sr effect on osteo-
blasts is multiphasic and dose dependent [24,25]. In the present
study, the SrHA selected for the in vivo implantation was based
on a cumulative Sr release in vitro comparable with optimal con-
centrations proposed in other in vitro studies [24,25].
In the present study, among the three SrHA preparations
(SrHA005, SrHA025 and SrHA050) only the material with the high-
est level of Sr substitution in the HA (SrHA050) was used in the
in vivo experiment. The main reason for this selection was that
the in vitro release experiment showed that this group demon-
strated the highest range of Sr ion (0.2–1.5 mM) while exhibiting
a relatively stable low release of Ca and P, compared to the other
two SrHA preparations. The selection of the SrHA preparation that
released up to 1.5 mM Sr (SrHA050) is in accordance with previous
in vitro studies showing that this range of Sr concentration is the
most effective to induce anti-osteoclastic or both anti-
osteoclastic and pro-osteoblastic responses [8,9,26]. On the other
hand, Sr in low quantity in a magnesium-based alloy (2% Sr)
induced new, fully mineralized trabecular bone, which remained
in direct contact with the implanted material, as compared to sim-
ilar alloy but with higher quantity of Sr (5%) [27]. Nevertheless,
direct comparison between bone formation induced in the present
study by the SrHA (with 50% Sr) and that induced by the Mg–Zr–Sr
(with 2% Sr) [27] is hindered. This is due to major differences in the
type of implanted material, animal model and observation periods.
Several in vitro studies have shown evidence for both pro-
osteogenic (anabolic) and anti-resorptive (anti-catabolic) effects
of Sr on osteoblasts [7,28,29] and osteoclasts [9], respectively. This
has formed the prevailing hypothesis for using Sr as a dual acting
agent in combination with bone substitutes [30,31] and implants
[32]. In the present study, in order to explore the in vivo local effect
of Sr incorporation in bone substitute material, the bone healing
events were investigated in defects treated with a combination
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previously published report using SrCaP without membrane [13],
show that Sr-containing materials promote new bone formation
in the defect. Firstly, after 6 d of healing, among different substi-
tute materials, combining SrHA with the collagen membrane
resulted in a higher level of woven bone formation compared to
the membrane-alone treated defect. Secondly, at late time period,
28 d, the newly formed bone at the peripheral region of the defect
was significantly higher in conjunction with the SrCaP compared to
HA (both in normal and osteoporotic condition) [13]. These mor-
phological observations are in agreement with recent in vivo data
showing that incorporation of Sr with bone substitutes [33–35],
collagen membranes [36], and titanium implants [32,37,38]
enhance bone regeneration and osseointegration. Importantly,
the present results extend the previous observation by demon-
strating that the mechanism for this effect involves the reduction
of osteoclast number and activity as well as the reduction of osteo-
blast–osteoclast coupling without affecting the osteoblast anabolic
gene expression.
The early recruitment of cells was investigated in this study. The
results show that, irrespective of the presence or absence of the sub-
stitute materials, both monocytes/macrophages and osteoprogeni-
tors are recruited very rapidly to the site of bone healing.
However, it was evident that the presence, and the type, of the sub-
stitutematerial affected the cell recruitmentprocess. Thefirst line of
evidence in this studywas the generally higher proportion of CD68-
positive monocytes/macrophages in the defects filled with bone
substitutes comparedwith unfilled defects. The second piece of evi-
dencewas that the SrHAsignificantly downregulated the expression
of the major component of the cell recruitment axis, CXCR4. CXCR4
is a surface receptor expressed by various cells, including MSCs and
osteoprogenitors [39,40], aswell as osteoclast precursors [41]. In the
present study, the SrHA-induced downregulation of CXCR4, in par-
allel with reduced osteoclast activity and number, suggests that at
least part of the inhibitory effect of Sr on osteoclasts is exerted at
the level of osteoclast precursor recruitment.
It has been shown that the inflammatory response of mono-
cytes to biomaterials is affected by the material properties. For
example, sintering the HA particles at high temperature induces
changes in crystal shape and size, which has been shown to stim-
ulate monocytes to produce more inflammatory cytokines [42]. It
has also been suggested that needle- and irregular-shaped HA par-
ticles provoke a greater inflammatory response compared with
spherical particles [42]. In the present study, the sintered synthetic
HA granules (rough surface with irregular microparticles) induced
higher TNF-a activity at 3 d, compared with the DBB granules, with
a smooth surface and spherical microparticles. Furthermore, other
in vitro studies have shown that the incorporation of Sr with CaP
materials inhibits the production of TNF-a and IL-6 [43,44]. These
findings are in agreement with the present in vivo observations: IL-
6 and TNF-a expression levels were significantly reduced in defects
with SrHA granules at 12 h and 3 d, respectively, compared with
HA granules. Given the well-described role of pro-inflammatory
cytokines in osteoclastogenesis, the modulation of TNF-a at this
specific time point, 3 d, suggests an important role for this cytokine
in the differentiation of osteoclast precursors. Further, the lower
expression of TNF-a in the SrHA defect took place in parallel with
the downregulation of RANKL, the main stimulatory factor in the
formation of mature osteoclasts. This observation is in agreement
with recent in vitro data showing the lower production of TNF-a
and RANKL by macrophages and osteoblasts, respectively, when
these cells were separately exposed to strontium-doped calcium
polyphosphate particles in comparison with HA particles [45].
It has been suggested that the application of a membrane
during guided bone regeneration serves as a passive barrier,
preventing the migration of non-osteogenic cells to the defect site.In the present study, the membrane accumulated different cell
phenotypes at different time periods of implantation. The histolog-
ical observation of cells that had migrated into the membrane and
the immunohistochemical identification of two major cell popula-
tions, monocytes/macrophages and osteoprogenitors, inside the
membrane, at least partly contradict the prevailing view that the
membrane acts as a physical barrier to cells. Their presence instead
indicates that the membrane possesses properties that provide
cues for cell migration, adhesion and differentiation. In fact, the
present membrane, which consists of porcine, extracellular matrix
(ECM)-derived material with 90% collagen [46] and smaller
amounts of glycosaminoglycans [47], glycoproteins and growth
factors [48], may have bioactive properties of importance for bone
regeneration. Recent experimental studies have demonstrated that
this membrane promotes bone regeneration in the defect by
attracting cells which express and secrete growth factors inside
the membrane [49]. These events in the membrane were found
to be strongly correlated with bone regeneration in the defect.
In the present study, the Sprague Dawley rat was used as an
experimental animal model. This model has been extensively used
in bone tissue-engineering research, due to several advantages,
including the low cost, small size and the well-known age and
genetic background [50]. Moreover, there is considerable informa-
tion about the molecular mechanisms of bone healing that have
been obtained from fracture models in rodents [51–53]. Cellular
components, cytokines and growth factors are generally well con-
served between species and convey similar biological functions
during inflammation and tissue regeneration. For instance, apart
from proportional variations, monocyte subpopulations appear
similar in humans, mice, and rats, especially when based on the
expression of chemokine receptors, adhesion molecules, and differ-
ences in size and granularity [54,55]. On the other hand, there are
some drawbacks for the rat animal model, which include the rela-
tively high bone turnover and temporal variations in the rate of tis-
sue healing and regeneration. In addition, there are anatomical
disparities with larger animals and humans, such as the differences
in bone macro- and micro-structure (e.g. the lack of Haversian sys-
tem in the cortical bone [56]) as well as differences in the biome-
chanical properties). Taken together, it is worth to state that
whereas the present study provided knowledge on fundamental
biological processes of healing during bone augmentation and
GBR, a direct extrapolation of the data to human conditions should
be made with caution.
5. Conclusion
It is concluded that SrHA, but not DBB and HA, promotes early
bone regeneration in defects covered with a resorbable collagenous
membrane. The mechanism for the early SrHA-induced bone for-
mation involves a reduced number of osteoclasts and the downreg-
ulation of the osteoclastic CatK and CR and the osteoblastic RANKL.
These observations suggest that the effects of Sr in vivo are medi-
ated by a reduction in catabolic and osteoblast–osteoclast coupling
processes. The observation that monocytes/macrophages and
osteoprogenitors are recruited into the membrane per se indicates
that the membrane material may provide additional cues for
substitute-driven bone regeneration.
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